Cite
HARVARD Citation
Singh, R. et al. (2022). Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir. Clinical pharmacology & therapeutics. 112 (1), pp. 101-111. [Online].